FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
FSTX Financial Statements
Year
2021
2020
2019
2018
Current Assets
84.74M
26.07M
19.02M
49.29M
Cash & Short Term Investments
78.55M
18.53M
4.9M
47.64M
Cash And Cash Equivalents
78.55M
18.53M
4.9M
14.72M
Short Term Investments
0
0
25.75M
32.91M
Net Receivables
2.31M
4.01M
11.37M
0
Inventory
-2.31M
2.77M
2.41M
0
Other Current Assets
6.19M
759k
332k
1.65M
Non-Current Assets
38.28M
37.54M
19.46M
19.12M
Property, Plant & Equipment
4.17M
3.57M
2.03M
2.32M
Goodwill And Intangible Assets
33.66M
33.91M
17.37M
0
Goodwill
14.9M
14.93M
4.32M
0
Intangible Assets
18.77M
18.99M
13.05M
0
Long Term Investments
0
0
0
16.8M
Tax Assets
0
0
0
0
Other Non-Current Assets
451k
61k
56k
0
Other Assets
0
0
0
0
Total Assets
123.02M
63.61M
38.48M
68.41M
-
-
-
-
Current Liabilities
12.13M
16.98M
29.89M
4.25M
Accounts Payable
3.08M
4.6M
5.06M
1.88M
Short Term Debt
906k
539k
15.52M
0
Tax Payables
0
0
257k
0
Deferred Revenue
5.79M
300k
442k
0
Other Current Liabilities
2.36M
11.54M
8.88M
2.37M
Total Current Liabilities
12.13M
16.98M
29.89M
4.25M
Total Non-Current Liabilities
14.03M
3.64M
52k
8.7M
Long-Term Debt
12.33M
2.62M
52k
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
7k
576k
0
0
Other Non Current liabilities
1.69M
440k
0
8.7M
Total Liabilities
26.16M
20.61M
29.94M
12.95M
Other Liabilities
0
0
0
0
Stockholders Equity
96.86M
42.99M
8.54M
55.86M
Common Stock
2k
1k
1k
2k
Retained Earnings
-78.45M
-47.17M
-21.55M
-102.07M
Accumulated Other Comprehensive Income/Loss
-1.5M
-1.08M
-1.63M
0
Other Shareholders Equity
176.81M
91.24M
31.72M
157.93M
Total Liabilities and Stockholders Equity
123.02M
63.61M
38.48M
68.81M
Retained Earning Schedule
Year
2021
2020
2019
2018
Retained Earnings (Previous Year)
-47.17M
-21.55M
-102.07M
-79.21M
Net Income
-31.28M
-25.62M
-23.01M
-22.85M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-78.45M
-47.17M
-21.55M
-102.07M
Other Distributions
-31.28M
-25.62M
80.52M
-22.85M
PPE Schedule
Year
2021
2020
2019
2018
Gross PPE
4.17M
3.57M
2.03M
2.32M
Annual Depreciation
1.29M
1.14M
9.15M
288k
Capital Expenditure
-658k
-730k
-127k
-1.97M
Net PPE
3.53M
3.16M
-6.99M
4M
Intangible and Goodwill Schedule
Year
2021
2020
2019
2018
Acquisitions and Adjustments
-28k
10.61M
4.32M
0
Goodwill (Previous Year)
14.93M
4.32M
0
0
Goodwill
14.9M
14.93M
4.32M
0
All figures are in USD.
